nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—UGT1A1—Rifampicin—leprosy	0.0999	0.142	CbGbCtD
Sorafenib—ABCC2—Rifampicin—leprosy	0.0608	0.0863	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Rifampicin—leprosy	0.0406	0.0576	CbGbCtD
Sorafenib—CYP3A7—Rifampicin—leprosy	0.0406	0.0576	CbGbCtD
Sorafenib—CYP2B6—Rifampicin—leprosy	0.0387	0.0549	CbGbCtD
Sorafenib—CYP3A7—Dapsone—leprosy	0.0335	0.0476	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Dapsone—leprosy	0.0335	0.0476	CbGbCtD
Sorafenib—CYP3A5—Thalidomide—leprosy	0.0314	0.0446	CbGbCtD
Sorafenib—CYP3A5—Rifampicin—leprosy	0.0305	0.0432	CbGbCtD
Sorafenib—CYP2C8—Rifampicin—leprosy	0.0293	0.0416	CbGbCtD
Sorafenib—CYP2C19—Thalidomide—leprosy	0.0254	0.036	CbGbCtD
Sorafenib—CYP3A5—Dapsone—leprosy	0.0251	0.0357	CbGbCtD
Sorafenib—CYP2C19—Rifampicin—leprosy	0.0246	0.0349	CbGbCtD
Sorafenib—CYP2C8—Dapsone—leprosy	0.0242	0.0343	CbGbCtD
Sorafenib—CYP1A2—Thalidomide—leprosy	0.0234	0.0332	CbGbCtD
Sorafenib—CYP1A2—Rifampicin—leprosy	0.0227	0.0322	CbGbCtD
Sorafenib—CYP2C9—Thalidomide—leprosy	0.0211	0.0299	CbGbCtD
Sorafenib—CYP2C9—Rifampicin—leprosy	0.0204	0.029	CbGbCtD
Sorafenib—CYP2C19—Dapsone—leprosy	0.0203	0.0288	CbGbCtD
Sorafenib—ABCB1—Rifampicin—leprosy	0.0198	0.0281	CbGbCtD
Sorafenib—CYP2C9—Dapsone—leprosy	0.0169	0.0239	CbGbCtD
Sorafenib—CYP3A4—Rifampicin—leprosy	0.0119	0.0169	CbGbCtD
Sorafenib—CYP3A4—Dapsone—leprosy	0.0098	0.0139	CbGbCtD
Sorafenib—Hypoalbuminaemia—Dapsone—leprosy	0.00903	0.0732	CcSEcCtD
Sorafenib—Cholangitis—Thalidomide—leprosy	0.00582	0.0472	CcSEcCtD
Sorafenib—Mood alteration NOS—Thalidomide—leprosy	0.00503	0.0408	CcSEcCtD
Sorafenib—Disease progression—Thalidomide—leprosy	0.00462	0.0375	CcSEcCtD
Sorafenib—Nephrotic syndrome—Dapsone—leprosy	0.00408	0.0331	CcSEcCtD
Sorafenib—Gastrointestinal perforation—Thalidomide—leprosy	0.00387	0.0314	CcSEcCtD
Sorafenib—Peripheral sensory neuropathy—Thalidomide—leprosy	0.00353	0.0286	CcSEcCtD
Sorafenib—Lipase increased—Thalidomide—leprosy	0.00343	0.0278	CcSEcCtD
Sorafenib—CDK7—Sulfathiazole—Dapsone—leprosy	0.0034	1	CbGdCrCtD
Sorafenib—Thromboembolism—Thalidomide—leprosy	0.00317	0.0257	CcSEcCtD
Sorafenib—KDR—hindlimb—leprosy	0.00294	0.0299	CbGeAlD
Sorafenib—MUSK—tendon—leprosy	0.00269	0.0274	CbGeAlD
Sorafenib—TIE1—blood vessel—leprosy	0.00259	0.0263	CbGeAlD
Sorafenib—KDR—appendage—leprosy	0.00252	0.0257	CbGeAlD
Sorafenib—Proteinuria—Dapsone—leprosy	0.00224	0.0182	CcSEcCtD
Sorafenib—MUSK—testis—leprosy	0.00223	0.0227	CbGeAlD
Sorafenib—Ascites—Thalidomide—leprosy	0.00222	0.018	CcSEcCtD
Sorafenib—Protein urine present—Dapsone—leprosy	0.00221	0.0179	CcSEcCtD
Sorafenib—MUSK—nervous system—leprosy	0.00219	0.0223	CbGeAlD
Sorafenib—Aphthous stomatitis—Thalidomide—leprosy	0.00215	0.0175	CcSEcCtD
Sorafenib—FLT4—blood vessel—leprosy	0.00214	0.0217	CbGeAlD
Sorafenib—Transient ischaemic attack—Thalidomide—leprosy	0.002	0.0162	CcSEcCtD
Sorafenib—Embolism venous—Thalidomide—leprosy	0.002	0.0162	CcSEcCtD
Sorafenib—CDKL3—testis—leprosy	0.00199	0.0202	CbGeAlD
Sorafenib—Lymphopenia—Thalidomide—leprosy	0.00197	0.016	CcSEcCtD
Sorafenib—Skin exfoliation—Dapsone—leprosy	0.00188	0.0153	CcSEcCtD
Sorafenib—KIT—skin epidermis—leprosy	0.00186	0.0189	CbGeAlD
Sorafenib—CDKL2—testis—leprosy	0.00182	0.0185	CbGeAlD
Sorafenib—CDKL2—nervous system—leprosy	0.00178	0.0182	CbGeAlD
Sorafenib—FLT1—blood vessel—leprosy	0.00166	0.0169	CbGeAlD
Sorafenib—MAPK15—testis—leprosy	0.00164	0.0167	CbGeAlD
Sorafenib—MAPK15—nervous system—leprosy	0.00161	0.0163	CbGeAlD
Sorafenib—Embolism—Thalidomide—leprosy	0.00157	0.0127	CcSEcCtD
Sorafenib—Hypothyroidism—Thalidomide—leprosy	0.00157	0.0127	CcSEcCtD
Sorafenib—ZAK—eye—leprosy	0.0015	0.0153	CbGeAlD
Sorafenib—Interstitial lung disease—Thalidomide—leprosy	0.00143	0.0116	CcSEcCtD
Sorafenib—KDR—blood vessel—leprosy	0.0014	0.0143	CbGeAlD
Sorafenib—Pleural effusion—Thalidomide—leprosy	0.00132	0.0107	CcSEcCtD
Sorafenib—Nasopharyngitis—Dapsone—leprosy	0.00128	0.0104	CcSEcCtD
Sorafenib—EPHX2—eye—leprosy	0.00126	0.0128	CbGeAlD
Sorafenib—Myocardial ischaemia—Thalidomide—leprosy	0.00126	0.0102	CcSEcCtD
Sorafenib—KIT—blood vessel—leprosy	0.00124	0.0127	CbGeAlD
Sorafenib—Endocrine disorder—Thalidomide—leprosy	0.00122	0.00987	CcSEcCtD
Sorafenib—PDGFRB—blood vessel—leprosy	0.00122	0.0124	CbGeAlD
Sorafenib—Pancreatitis—Dapsone—leprosy	0.00121	0.00983	CcSEcCtD
Sorafenib—Proteinuria—Thalidomide—leprosy	0.00115	0.00931	CcSEcCtD
Sorafenib—TAOK2—tendon—leprosy	0.00114	0.0116	CbGeAlD
Sorafenib—FLT4—eye—leprosy	0.00114	0.0116	CbGeAlD
Sorafenib—AURKC—tendon—leprosy	0.00113	0.0116	CbGeAlD
Sorafenib—Protein urine present—Thalidomide—leprosy	0.00113	0.00918	CcSEcCtD
Sorafenib—Bone disorder—Thalidomide—leprosy	0.00112	0.00906	CcSEcCtD
Sorafenib—Hypocalcaemia—Thalidomide—leprosy	0.0011	0.00894	CcSEcCtD
Sorafenib—HIPK4—testis—leprosy	0.0011	0.0112	CbGeAlD
Sorafenib—Drug interaction—Thalidomide—leprosy	0.00109	0.00882	CcSEcCtD
Sorafenib—Neuropathy peripheral—Dapsone—leprosy	0.00108	0.00877	CcSEcCtD
Sorafenib—MKNK2—eye—leprosy	0.00103	0.0105	CbGeAlD
Sorafenib—MKNK1—eye—leprosy	0.00102	0.0103	CbGeAlD
Sorafenib—ZAK—tendon—leprosy	0.000996	0.0101	CbGeAlD
Sorafenib—HIPK3—tendon—leprosy	0.000975	0.00992	CbGeAlD
Sorafenib—MAPK11—testis—leprosy	0.00097	0.00988	CbGeAlD
Sorafenib—Skin exfoliation—Thalidomide—leprosy	0.000963	0.00781	CcSEcCtD
Sorafenib—CDK7—testis—leprosy	0.000954	0.00972	CbGeAlD
Sorafenib—MAPK11—nervous system—leprosy	0.000952	0.00969	CbGeAlD
Sorafenib—Neuropathy—Thalidomide—leprosy	0.000947	0.00768	CcSEcCtD
Sorafenib—TAOK2—testis—leprosy	0.000947	0.00964	CbGeAlD
Sorafenib—AURKC—testis—leprosy	0.00094	0.00956	CbGeAlD
Sorafenib—CDK7—nervous system—leprosy	0.000937	0.00953	CbGeAlD
Sorafenib—RALBP1—eye—leprosy	0.000929	0.00946	CbGeAlD
Sorafenib—Tinnitus—Dapsone—leprosy	0.000923	0.00748	CcSEcCtD
Sorafenib—AURKC—nervous system—leprosy	0.000922	0.00939	CbGeAlD
Sorafenib—Gynaecomastia—Thalidomide—leprosy	0.000903	0.00732	CcSEcCtD
Sorafenib—FLT1—eye—leprosy	0.000884	0.009	CbGeAlD
Sorafenib—RAF1—eye—leprosy	0.000879	0.00895	CbGeAlD
Sorafenib—BRAF—tendon—leprosy	0.000874	0.00889	CbGeAlD
Sorafenib—EPHA6—testis—leprosy	0.00087	0.00886	CbGeAlD
Sorafenib—Erythema—Dapsone—leprosy	0.000862	0.00699	CcSEcCtD
Sorafenib—EPHA6—nervous system—leprosy	0.000854	0.00869	CbGeAlD
Sorafenib—EPHX2—tendon—leprosy	0.000835	0.0085	CbGeAlD
Sorafenib—ZAK—testis—leprosy	0.000825	0.0084	CbGeAlD
Sorafenib—Eczema—Thalidomide—leprosy	0.000815	0.00661	CcSEcCtD
Sorafenib—ZAK—nervous system—leprosy	0.00081	0.00824	CbGeAlD
Sorafenib—Cardiac failure congestive—Thalidomide—leprosy	0.000808	0.00655	CcSEcCtD
Sorafenib—HIPK3—testis—leprosy	0.000807	0.00822	CbGeAlD
Sorafenib—Renal failure acute—Thalidomide—leprosy	0.000793	0.00643	CcSEcCtD
Sorafenib—MAP3K19—testis—leprosy	0.000791	0.00805	CbGeAlD
Sorafenib—Dermatitis exfoliative—Thalidomide—leprosy	0.000776	0.0063	CcSEcCtD
Sorafenib—MAP3K19—nervous system—leprosy	0.000776	0.0079	CbGeAlD
Sorafenib—RAF1—skin of body—leprosy	0.000765	0.00778	CbGeAlD
Sorafenib—EPHB6—skin of body—leprosy	0.00076	0.00774	CbGeAlD
Sorafenib—TIE1—testis—leprosy	0.000754	0.00768	CbGeAlD
Sorafenib—Cough—Dapsone—leprosy	0.000752	0.0061	CcSEcCtD
Sorafenib—Cardiac failure—Thalidomide—leprosy	0.000751	0.00609	CcSEcCtD
Sorafenib—KDR—eye—leprosy	0.000747	0.00761	CbGeAlD
Sorafenib—FGFR1—tendon—leprosy	0.000743	0.00756	CbGeAlD
Sorafenib—TIE1—nervous system—leprosy	0.00074	0.00754	CbGeAlD
Sorafenib—Hyponatraemia—Thalidomide—leprosy	0.000735	0.00596	CcSEcCtD
Sorafenib—Pain in extremity—Thalidomide—leprosy	0.000733	0.00594	CcSEcCtD
Sorafenib—CSF1R—eye—leprosy	0.000729	0.00742	CbGeAlD
Sorafenib—BRAF—testis—leprosy	0.000723	0.00736	CbGeAlD
Sorafenib—MAP3K7—tendon—leprosy	0.000703	0.00716	CbGeAlD
Sorafenib—Mood swings—Thalidomide—leprosy	0.000694	0.00563	CcSEcCtD
Sorafenib—EPHX2—testis—leprosy	0.000691	0.00704	CbGeAlD
Sorafenib—FLT3—testis—leprosy	0.000686	0.00699	CbGeAlD
Sorafenib—MKNK2—tendon—leprosy	0.000682	0.00694	CbGeAlD
Sorafenib—Dehydration—Thalidomide—leprosy	0.000681	0.00552	CcSEcCtD
Sorafenib—Dry skin—Thalidomide—leprosy	0.000671	0.00544	CcSEcCtD
Sorafenib—Hypokalaemia—Thalidomide—leprosy	0.000667	0.00541	CcSEcCtD
Sorafenib—RET—tendon—leprosy	0.000665	0.00677	CbGeAlD
Sorafenib—Breast disorder—Thalidomide—leprosy	0.000662	0.00537	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Thalidomide—leprosy	0.00066	0.00535	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Thalidomide—leprosy	0.00066	0.00535	CcSEcCtD
Sorafenib—PDGFRB—eye—leprosy	0.000647	0.00658	CbGeAlD
Sorafenib—Alanine aminotransferase increased—Thalidomide—leprosy	0.000646	0.00524	CcSEcCtD
Sorafenib—CSF1R—skin of body—leprosy	0.000634	0.00646	CbGeAlD
Sorafenib—Dysphagia—Thalidomide—leprosy	0.000633	0.00513	CcSEcCtD
Sorafenib—FLT4—testis—leprosy	0.000623	0.00635	CbGeAlD
Sorafenib—Pancreatitis—Thalidomide—leprosy	0.000621	0.00503	CcSEcCtD
Sorafenib—RALBP1—tendon—leprosy	0.000615	0.00626	CbGeAlD
Sorafenib—FGFR1—testis—leprosy	0.000615	0.00626	CbGeAlD
Sorafenib—Neutropenia—Thalidomide—leprosy	0.000592	0.0048	CcSEcCtD
Sorafenib—FLT1—tendon—leprosy	0.000585	0.00596	CbGeAlD
Sorafenib—Erectile dysfunction—Thalidomide—leprosy	0.000583	0.00473	CcSEcCtD
Sorafenib—MAP3K7—testis—leprosy	0.000582	0.00593	CbGeAlD
Sorafenib—RAF1—tendon—leprosy	0.000582	0.00592	CbGeAlD
Sorafenib—EPHB6—tendon—leprosy	0.000579	0.00589	CbGeAlD
Sorafenib—KIT—skin of body—leprosy	0.000576	0.00586	CbGeAlD
Sorafenib—Gastrointestinal pain—Dapsone—leprosy	0.000575	0.00466	CcSEcCtD
Sorafenib—Weight decreased—Thalidomide—leprosy	0.000573	0.00464	CcSEcCtD
Sorafenib—Pneumonia—Thalidomide—leprosy	0.000568	0.0046	CcSEcCtD
Sorafenib—Infestation—Thalidomide—leprosy	0.000564	0.00458	CcSEcCtD
Sorafenib—Infestation NOS—Thalidomide—leprosy	0.000564	0.00458	CcSEcCtD
Sorafenib—MKNK2—testis—leprosy	0.000564	0.00574	CbGeAlD
Sorafenib—PDGFRB—skin of body—leprosy	0.000563	0.00573	CbGeAlD
Sorafenib—Stevens-Johnson syndrome—Thalidomide—leprosy	0.00056	0.00454	CcSEcCtD
Sorafenib—MKNK1—testis—leprosy	0.000557	0.00567	CbGeAlD
Sorafenib—Acute coronary syndrome—Thalidomide—leprosy	0.000556	0.00451	CcSEcCtD
Sorafenib—Abdominal pain—Dapsone—leprosy	0.000556	0.00451	CcSEcCtD
Sorafenib—Body temperature increased—Dapsone—leprosy	0.000556	0.00451	CcSEcCtD
Sorafenib—Renal failure—Thalidomide—leprosy	0.000555	0.0045	CcSEcCtD
Sorafenib—STK10—tendon—leprosy	0.000554	0.00564	CbGeAlD
Sorafenib—MKNK2—nervous system—leprosy	0.000554	0.00564	CbGeAlD
Sorafenib—Myocardial infarction—Thalidomide—leprosy	0.000553	0.00449	CcSEcCtD
Sorafenib—Neuropathy peripheral—Thalidomide—leprosy	0.000553	0.00449	CcSEcCtD
Sorafenib—RET—testis—leprosy	0.00055	0.0056	CbGeAlD
Sorafenib—Stomatitis—Thalidomide—leprosy	0.00055	0.00446	CcSEcCtD
Sorafenib—PDGFRA—tendon—leprosy	0.000549	0.00558	CbGeAlD
Sorafenib—MKNK1—nervous system—leprosy	0.000547	0.00557	CbGeAlD
Sorafenib—RET—nervous system—leprosy	0.00054	0.0055	CbGeAlD
Sorafenib—Epistaxis—Thalidomide—leprosy	0.000532	0.00432	CcSEcCtD
Sorafenib—RALBP1—testis—leprosy	0.00051	0.00519	CbGeAlD
Sorafenib—Urinary tract disorder—Thalidomide—leprosy	0.0005	0.00406	CcSEcCtD
Sorafenib—RALBP1—nervous system—leprosy	0.0005	0.00509	CbGeAlD
Sorafenib—Urethral disorder—Thalidomide—leprosy	0.000497	0.00403	CcSEcCtD
Sorafenib—KDR—tendon—leprosy	0.000495	0.00504	CbGeAlD
Sorafenib—MAP2K5—tendon—leprosy	0.000495	0.00504	CbGeAlD
Sorafenib—FLT1—testis—leprosy	0.000485	0.00493	CbGeAlD
Sorafenib—CSF1R—tendon—leprosy	0.000483	0.00492	CbGeAlD
Sorafenib—RAF1—testis—leprosy	0.000482	0.00491	CbGeAlD
Sorafenib—EPHB6—testis—leprosy	0.000479	0.00488	CbGeAlD
Sorafenib—Erythema multiforme—Thalidomide—leprosy	0.000479	0.00389	CcSEcCtD
Sorafenib—FLT1—nervous system—leprosy	0.000476	0.00484	CbGeAlD
Sorafenib—RAF1—nervous system—leprosy	0.000473	0.00481	CbGeAlD
Sorafenib—Tinnitus—Thalidomide—leprosy	0.000472	0.00383	CcSEcCtD
Sorafenib—Cardiac disorder—Thalidomide—leprosy	0.00047	0.00381	CcSEcCtD
Sorafenib—EPHB6—nervous system—leprosy	0.00047	0.00479	CbGeAlD
Sorafenib—Angiopathy—Thalidomide—leprosy	0.00046	0.00373	CcSEcCtD
Sorafenib—STK10—testis—leprosy	0.000459	0.00467	CbGeAlD
Sorafenib—Immune system disorder—Thalidomide—leprosy	0.000458	0.00371	CcSEcCtD
Sorafenib—Mediastinal disorder—Thalidomide—leprosy	0.000457	0.0037	CcSEcCtD
Sorafenib—PDGFRA—testis—leprosy	0.000454	0.00462	CbGeAlD
Sorafenib—Arrhythmia—Thalidomide—leprosy	0.000453	0.00367	CcSEcCtD
Sorafenib—STK10—nervous system—leprosy	0.00045	0.00458	CbGeAlD
Sorafenib—Alopecia—Thalidomide—leprosy	0.000448	0.00363	CcSEcCtD
Sorafenib—Vomiting—Dapsone—leprosy	0.000447	0.00363	CcSEcCtD
Sorafenib—PDGFRA—nervous system—leprosy	0.000446	0.00454	CbGeAlD
Sorafenib—HTR2B—skin of body—leprosy	0.000446	0.00454	CbGeAlD
Sorafenib—Mental disorder—Thalidomide—leprosy	0.000444	0.0036	CcSEcCtD
Sorafenib—Malnutrition—Thalidomide—leprosy	0.000441	0.00358	CcSEcCtD
Sorafenib—Headache—Dapsone—leprosy	0.000441	0.00357	CcSEcCtD
Sorafenib—Dysgeusia—Thalidomide—leprosy	0.000432	0.0035	CcSEcCtD
Sorafenib—PDGFRB—tendon—leprosy	0.000428	0.00436	CbGeAlD
Sorafenib—Muscle spasms—Thalidomide—leprosy	0.000424	0.00344	CcSEcCtD
Sorafenib—Nausea—Dapsone—leprosy	0.000418	0.00339	CcSEcCtD
Sorafenib—KDR—testis—leprosy	0.00041	0.00417	CbGeAlD
Sorafenib—MAP2K5—testis—leprosy	0.00041	0.00417	CbGeAlD
Sorafenib—Anaemia—Thalidomide—leprosy	0.000408	0.00331	CcSEcCtD
Sorafenib—Angioedema—Thalidomide—leprosy	0.000403	0.00327	CcSEcCtD
Sorafenib—MAP2K5—nervous system—leprosy	0.000402	0.00409	CbGeAlD
Sorafenib—KDR—nervous system—leprosy	0.000402	0.00409	CbGeAlD
Sorafenib—CSF1R—testis—leprosy	0.0004	0.00407	CbGeAlD
Sorafenib—Syncope—Thalidomide—leprosy	0.000396	0.00321	CcSEcCtD
Sorafenib—Leukopenia—Thalidomide—leprosy	0.000395	0.0032	CcSEcCtD
Sorafenib—CSF1R—nervous system—leprosy	0.000392	0.004	CbGeAlD
Sorafenib—Loss of consciousness—Thalidomide—leprosy	0.000388	0.00314	CcSEcCtD
Sorafenib—Cough—Thalidomide—leprosy	0.000385	0.00312	CcSEcCtD
Sorafenib—Hypertension—Thalidomide—leprosy	0.000381	0.00309	CcSEcCtD
Sorafenib—Myalgia—Thalidomide—leprosy	0.000376	0.00305	CcSEcCtD
Sorafenib—Arthralgia—Thalidomide—leprosy	0.000376	0.00305	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000373	0.00302	CcSEcCtD
Sorafenib—Dry mouth—Thalidomide—leprosy	0.000367	0.00298	CcSEcCtD
Sorafenib—KIT—testis—leprosy	0.000363	0.0037	CbGeAlD
Sorafenib—Infection—Thalidomide—leprosy	0.000358	0.0029	CcSEcCtD
Sorafenib—KIT—nervous system—leprosy	0.000356	0.00363	CbGeAlD
Sorafenib—PDGFRB—testis—leprosy	0.000355	0.00361	CbGeAlD
Sorafenib—Shock—Thalidomide—leprosy	0.000354	0.00287	CcSEcCtD
Sorafenib—Nervous system disorder—Thalidomide—leprosy	0.000353	0.00286	CcSEcCtD
Sorafenib—Thrombocytopenia—Thalidomide—leprosy	0.000352	0.00286	CcSEcCtD
Sorafenib—Skin disorder—Thalidomide—leprosy	0.00035	0.00284	CcSEcCtD
Sorafenib—PDGFRB—nervous system—leprosy	0.000348	0.00354	CbGeAlD
Sorafenib—Anorexia—Thalidomide—leprosy	0.000343	0.00278	CcSEcCtD
Sorafenib—ABCC4—tendon—leprosy	0.000341	0.00347	CbGeAlD
Sorafenib—HTR2B—tendon—leprosy	0.000339	0.00345	CbGeAlD
Sorafenib—ABCB1—blood vessel—leprosy	0.000337	0.00343	CbGeAlD
Sorafenib—ABCC2—tendon—leprosy	0.00033	0.00336	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Thalidomide—leprosy	0.000328	0.00266	CcSEcCtD
Sorafenib—Dyspnoea—Thalidomide—leprosy	0.000321	0.0026	CcSEcCtD
Sorafenib—Dyspepsia—Thalidomide—leprosy	0.000317	0.00257	CcSEcCtD
Sorafenib—Decreased appetite—Thalidomide—leprosy	0.000313	0.00254	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Thalidomide—leprosy	0.000311	0.00252	CcSEcCtD
Sorafenib—Fatigue—Thalidomide—leprosy	0.00031	0.00252	CcSEcCtD
Sorafenib—Pain—Thalidomide—leprosy	0.000308	0.0025	CcSEcCtD
Sorafenib—Constipation—Thalidomide—leprosy	0.000308	0.0025	CcSEcCtD
Sorafenib—Gastrointestinal pain—Thalidomide—leprosy	0.000294	0.00239	CcSEcCtD
Sorafenib—HTR2C—nervous system—leprosy	0.000293	0.00299	CbGeAlD
Sorafenib—CYP2B6—skin of body—leprosy	0.000292	0.00297	CbGeAlD
Sorafenib—Urticaria—Thalidomide—leprosy	0.000286	0.00232	CcSEcCtD
Sorafenib—Body temperature increased—Thalidomide—leprosy	0.000285	0.00231	CcSEcCtD
Sorafenib—Abdominal pain—Thalidomide—leprosy	0.000285	0.00231	CcSEcCtD
Sorafenib—ABCC4—testis—leprosy	0.000282	0.00287	CbGeAlD
Sorafenib—ABCC4—nervous system—leprosy	0.000277	0.00282	CbGeAlD
Sorafenib—HTR2B—nervous system—leprosy	0.000276	0.00281	CbGeAlD
Sorafenib—ABCC2—testis—leprosy	0.000273	0.00278	CbGeAlD
Sorafenib—Hypersensitivity—Thalidomide—leprosy	0.000265	0.00215	CcSEcCtD
Sorafenib—Asthenia—Thalidomide—leprosy	0.000258	0.00209	CcSEcCtD
Sorafenib—Pruritus—Thalidomide—leprosy	0.000255	0.00207	CcSEcCtD
Sorafenib—Diarrhoea—Thalidomide—leprosy	0.000246	0.002	CcSEcCtD
Sorafenib—Dizziness—Thalidomide—leprosy	0.000238	0.00193	CcSEcCtD
Sorafenib—Vomiting—Thalidomide—leprosy	0.000229	0.00186	CcSEcCtD
Sorafenib—Rash—Thalidomide—leprosy	0.000227	0.00184	CcSEcCtD
Sorafenib—Dermatitis—Thalidomide—leprosy	0.000227	0.00184	CcSEcCtD
Sorafenib—Headache—Thalidomide—leprosy	0.000226	0.00183	CcSEcCtD
Sorafenib—Nausea—Thalidomide—leprosy	0.000214	0.00173	CcSEcCtD
Sorafenib—CYP2C8—testis—leprosy	0.000205	0.00209	CbGeAlD
Sorafenib—ABCG2—testis—leprosy	0.000199	0.00203	CbGeAlD
Sorafenib—CYP2B6—testis—leprosy	0.000184	0.00187	CbGeAlD
Sorafenib—CYP2B6—nervous system—leprosy	0.00018	0.00184	CbGeAlD
Sorafenib—CYP2D6—testis—leprosy	0.000137	0.00139	CbGeAlD
Sorafenib—CYP3A4—nervous system—leprosy	0.000136	0.00139	CbGeAlD
Sorafenib—CYP2D6—nervous system—leprosy	0.000134	0.00137	CbGeAlD
Sorafenib—ABCB1—testis—leprosy	9.83e-05	0.001	CbGeAlD
Sorafenib—ABCB1—nervous system—leprosy	9.65e-05	0.000982	CbGeAlD
Sorafenib—PDGFRA—Adaptive Immune System—PARK2—leprosy	8.55e-05	0.00121	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—NOD2—leprosy	8.42e-05	0.00119	CbGpPWpGaD
Sorafenib—ABCC4—Transmembrane transport of small molecules—SLC11A1—leprosy	8.17e-05	0.00116	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—CYLD—leprosy	8.09e-05	0.00115	CbGpPWpGaD
Sorafenib—MAP3K7—Toll-like Receptor Signaling Pathway—TNF—leprosy	8e-05	0.00113	CbGpPWpGaD
Sorafenib—RAF1—Signaling by Interleukins—IL2—leprosy	7.97e-05	0.00113	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—PARK2—leprosy	7.7e-05	0.00109	CbGpPWpGaD
Sorafenib—CDK7—Disease—SLC11A1—leprosy	7.67e-05	0.00109	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—RIPK2—leprosy	7.6e-05	0.00108	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—TLR2—leprosy	7.6e-05	0.00108	CbGpPWpGaD
Sorafenib—MAP3K7—Cytokine Signaling in Immune system—HLA-DRB1—leprosy	7.54e-05	0.00107	CbGpPWpGaD
Sorafenib—ABCB1—Allograft Rejection—HLA-DRB1—leprosy	7.44e-05	0.00105	CbGpPWpGaD
Sorafenib—MAP2K5—MAPK Signaling Pathway—TNF—leprosy	7.1e-05	0.00101	CbGpPWpGaD
Sorafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	7.1e-05	0.00101	CbGpPWpGaD
Sorafenib—MAPK11—Regulation of toll-like receptor signaling pathway—TNF—leprosy	6.92e-05	0.000981	CbGpPWpGaD
Sorafenib—ABCC2—Transmembrane transport of small molecules—SLC11A1—leprosy	6.89e-05	0.000977	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—NOD2—leprosy	6.89e-05	0.000977	CbGpPWpGaD
Sorafenib—RAF1—Transmembrane transport of small molecules—SLC11A1—leprosy	6.87e-05	0.000974	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CYLD—leprosy	6.87e-05	0.000974	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—PARK2—leprosy	6.86e-05	0.000973	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—RIPK2—leprosy	6.85e-05	0.000971	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—RIPK2—leprosy	6.85e-05	0.000971	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—TLR2—leprosy	6.85e-05	0.000971	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—TLR2—leprosy	6.85e-05	0.000971	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—RIPK2—leprosy	6.82e-05	0.000966	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—RIPK2—leprosy	6.71e-05	0.00095	CbGpPWpGaD
Sorafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	6.69e-05	0.000947	CbGpPWpGaD
Sorafenib—RAF1—TNF alpha Signaling Pathway—TNF—leprosy	6.6e-05	0.000936	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—RIPK2—leprosy	6.58e-05	0.000933	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—RIPK2—leprosy	6.58e-05	0.000933	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—RIPK2—leprosy	6.51e-05	0.000922	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—TLR2—leprosy	6.51e-05	0.000922	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—RIPK2—leprosy	6.49e-05	0.000919	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—TLR2—leprosy	6.49e-05	0.000919	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—RIPK2—leprosy	6.25e-05	0.000885	CbGpPWpGaD
Sorafenib—MAP3K7—Regulation of toll-like receptor signaling pathway—TNF—leprosy	6.24e-05	0.000885	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—RIPK2—leprosy	6.23e-05	0.000883	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—NOD2—leprosy	6.21e-05	0.000881	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—NOD2—leprosy	6.21e-05	0.000881	CbGpPWpGaD
Sorafenib—KIT—Immune System—CYLD—leprosy	6.2e-05	0.000878	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CYLD—leprosy	6.2e-05	0.000878	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—PARK2—leprosy	6.07e-05	0.000861	CbGpPWpGaD
Sorafenib—ABCG2—Transmembrane transport of small molecules—SLC11A1—leprosy	5.99e-05	0.000849	CbGpPWpGaD
Sorafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	5.94e-05	0.000842	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—NOD2—leprosy	5.9e-05	0.000836	CbGpPWpGaD
Sorafenib—BRAF—MAPK Signaling Pathway—TNF—leprosy	5.9e-05	0.000835	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—NOD2—leprosy	5.88e-05	0.000834	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CYLD—leprosy	5.88e-05	0.000833	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CYLD—leprosy	5.86e-05	0.000831	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—RIPK2—leprosy	5.85e-05	0.000828	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—TLR2—leprosy	5.85e-05	0.000828	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—HLA-DRB1—leprosy	5.73e-05	0.000812	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—RIPK2—leprosy	5.61e-05	0.000795	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—RIPK2—leprosy	5.56e-05	0.000787	CbGpPWpGaD
Sorafenib—BRAF—Disease—SLC11A1—leprosy	5.56e-05	0.000787	CbGpPWpGaD
Sorafenib—MAP3K7—Cytokine Signaling in Immune system—IFNG—leprosy	5.51e-05	0.000781	CbGpPWpGaD
Sorafenib—KIT—Immune System—PARK2—leprosy	5.48e-05	0.000776	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—PARK2—leprosy	5.48e-05	0.000776	CbGpPWpGaD
Sorafenib—ABCB1—Allograft Rejection—IFNG—leprosy	5.43e-05	0.00077	CbGpPWpGaD
Sorafenib—MAP3K7—MAPK Signaling Pathway—TNF—leprosy	5.37e-05	0.00076	CbGpPWpGaD
Sorafenib—ABCC4—Platelet activation, signaling and aggregation—IL2—leprosy	5.35e-05	0.000758	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—NOD2—leprosy	5.3e-05	0.000751	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CYLD—leprosy	5.28e-05	0.000749	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—RIPK2—leprosy	5.21e-05	0.000738	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—TLR2—leprosy	5.21e-05	0.000738	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—PARK2—leprosy	5.2e-05	0.000737	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—PARK2—leprosy	5.18e-05	0.000735	CbGpPWpGaD
Sorafenib—FGFR1—MAPK Signaling Pathway—TNF—leprosy	5.09e-05	0.000722	CbGpPWpGaD
Sorafenib—KIT—Disease—SLC11A1—leprosy	5.06e-05	0.000717	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—CD40LG—leprosy	5.05e-05	0.000715	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—CD40LG—leprosy	5.05e-05	0.000715	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—RIPK2—leprosy	5e-05	0.000709	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—RIPK2—leprosy	5e-05	0.000709	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—CD8A—leprosy	4.99e-05	0.000707	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—CD8A—leprosy	4.99e-05	0.000707	CbGpPWpGaD
Sorafenib—MAP3K7—Cytokine Signaling in Immune system—IL2—leprosy	4.9e-05	0.000694	CbGpPWpGaD
Sorafenib—ABCB1—Allograft Rejection—IL2—leprosy	4.83e-05	0.000684	CbGpPWpGaD
Sorafenib—FGFR1—Disease—SLC11A1—leprosy	4.8e-05	0.00068	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—CD40LG—leprosy	4.79e-05	0.000678	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—SLC11A1—leprosy	4.79e-05	0.000678	CbGpPWpGaD
Sorafenib—EPHB6—Developmental Biology—TNF—leprosy	4.78e-05	0.000677	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—CD40LG—leprosy	4.78e-05	0.000677	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—CD8A—leprosy	4.73e-05	0.000671	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—NOD2—leprosy	4.72e-05	0.000669	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—CD8A—leprosy	4.72e-05	0.000669	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CYLD—leprosy	4.71e-05	0.000667	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—PARK2—leprosy	4.67e-05	0.000662	CbGpPWpGaD
Sorafenib—FGFR1—Integrated Pancreatic Cancer Pathway—TNF—leprosy	4.6e-05	0.000651	CbGpPWpGaD
Sorafenib—PDGFRA—Integrated Pancreatic Cancer Pathway—TNF—leprosy	4.58e-05	0.00065	CbGpPWpGaD
Sorafenib—PDGFRB—MAPK Signaling Pathway—TNF—leprosy	4.58e-05	0.000648	CbGpPWpGaD
Sorafenib—RAF1—Platelet activation, signaling and aggregation—IL2—leprosy	4.5e-05	0.000637	CbGpPWpGaD
Sorafenib—EPHA6—Developmental Biology—TNF—leprosy	4.49e-05	0.000637	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—RIPK2—leprosy	4.43e-05	0.000627	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—TLR2—leprosy	4.43e-05	0.000627	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—SDHD—leprosy	4.4e-05	0.000624	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—SDHD—leprosy	4.4e-05	0.000624	CbGpPWpGaD
Sorafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	4.33e-05	0.000613	CbGpPWpGaD
Sorafenib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—leprosy	4.33e-05	0.000613	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—SLC11A1—leprosy	4.31e-05	0.000611	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—CD40LG—leprosy	4.3e-05	0.00061	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—CD8A—leprosy	4.25e-05	0.000603	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—IFNG—leprosy	4.19e-05	0.000593	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PARK2—leprosy	4.16e-05	0.00059	CbGpPWpGaD
Sorafenib—RAF1—MAPK Signaling Pathway—TNF—leprosy	4.08e-05	0.000578	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—HLA-DRB1—leprosy	4.06e-05	0.000576	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—HLA-DRB1—leprosy	4.06e-05	0.000576	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—NOD2—leprosy	4.01e-05	0.000569	CbGpPWpGaD
Sorafenib—KIT—Immune System—RIPK2—leprosy	3.99e-05	0.000566	CbGpPWpGaD
Sorafenib—KIT—Immune System—TLR2—leprosy	3.99e-05	0.000566	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—RIPK2—leprosy	3.99e-05	0.000566	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—TLR2—leprosy	3.99e-05	0.000566	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—HLA-DRB1—leprosy	3.86e-05	0.000546	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—HLA-DRB1—leprosy	3.85e-05	0.000545	CbGpPWpGaD
Sorafenib—RAF1—Disease—SLC11A1—leprosy	3.84e-05	0.000545	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—CD40LG—leprosy	3.83e-05	0.000543	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—CD8A—leprosy	3.79e-05	0.000537	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—TLR2—leprosy	3.79e-05	0.000537	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—RIPK2—leprosy	3.79e-05	0.000537	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—RIPK2—leprosy	3.78e-05	0.000536	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—TLR2—leprosy	3.78e-05	0.000536	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—SDHD—leprosy	3.74e-05	0.000529	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—IL2—leprosy	3.72e-05	0.000527	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—SDHD—leprosy	3.7e-05	0.000525	CbGpPWpGaD
Sorafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—leprosy	3.68e-05	0.000522	CbGpPWpGaD
Sorafenib—KIT—Immune System—NOD2—leprosy	3.62e-05	0.000513	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—NOD2—leprosy	3.62e-05	0.000513	CbGpPWpGaD
Sorafenib—ABCB1—Allograft Rejection—TNF—leprosy	3.52e-05	0.000498	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HLA-DRB1—leprosy	3.46e-05	0.000491	CbGpPWpGaD
Sorafenib—MKNK1—Disease—CD4—leprosy	3.45e-05	0.000489	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—NOD2—leprosy	3.44e-05	0.000487	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—NOD2—leprosy	3.43e-05	0.000486	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—RIPK2—leprosy	3.42e-05	0.000484	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—RIPK2—leprosy	3.4e-05	0.000482	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—TLR2—leprosy	3.4e-05	0.000482	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CD40LG—leprosy	3.39e-05	0.000481	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CD8A—leprosy	3.36e-05	0.000475	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—RIPK2—leprosy	3.33e-05	0.000472	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—CD4—leprosy	3.31e-05	0.000469	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—SLC11A1—leprosy	3.24e-05	0.000459	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HLA-DRB1—leprosy	3.09e-05	0.000438	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NOD2—leprosy	3.09e-05	0.000437	CbGpPWpGaD
Sorafenib—KIT—Immune System—CD40LG—leprosy	3.06e-05	0.000434	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CD40LG—leprosy	3.06e-05	0.000434	CbGpPWpGaD
Sorafenib—RAF1—Immune System—RIPK2—leprosy	3.03e-05	0.00043	CbGpPWpGaD
Sorafenib—RAF1—Immune System—TLR2—leprosy	3.03e-05	0.00043	CbGpPWpGaD
Sorafenib—KIT—Immune System—CD8A—leprosy	3.03e-05	0.000429	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CD8A—leprosy	3.03e-05	0.000429	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—CD4—leprosy	2.98e-05	0.000423	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—CD4—leprosy	2.98e-05	0.000423	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—TNF—leprosy	2.92e-05	0.000414	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CD40LG—leprosy	2.9e-05	0.000412	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD40LG—leprosy	2.9e-05	0.00041	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CD8A—leprosy	2.87e-05	0.000407	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—CD4—leprosy	2.87e-05	0.000406	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—CD4—leprosy	2.87e-05	0.000406	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD8A—leprosy	2.86e-05	0.000406	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—RIPK2—leprosy	2.86e-05	0.000406	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—RIPK2—leprosy	2.84e-05	0.000402	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—CD4—leprosy	2.83e-05	0.000401	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—CD4—leprosy	2.82e-05	0.0004	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—IL2—leprosy	2.76e-05	0.000391	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NOD2—leprosy	2.75e-05	0.00039	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—SDHD—leprosy	2.74e-05	0.000388	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HLA-DRB1—leprosy	2.73e-05	0.000387	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—IL2—leprosy	2.73e-05	0.000387	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—CD4—leprosy	2.72e-05	0.000385	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—CD4—leprosy	2.71e-05	0.000384	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—IL2—leprosy	2.69e-05	0.000381	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—SDHD—leprosy	2.68e-05	0.000379	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD40LG—leprosy	2.61e-05	0.00037	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—RIPK2—leprosy	2.58e-05	0.000366	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—RIPK2—leprosy	2.58e-05	0.000366	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD8A—leprosy	2.58e-05	0.000366	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—CD4—leprosy	2.54e-05	0.000361	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—TNF—leprosy	2.51e-05	0.000356	CbGpPWpGaD
Sorafenib—KIT—Immune System—HLA-DRB1—leprosy	2.46e-05	0.000349	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HLA-DRB1—leprosy	2.46e-05	0.000349	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—RIPK2—leprosy	2.45e-05	0.000347	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—RIPK2—leprosy	2.44e-05	0.000346	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—CD4—leprosy	2.44e-05	0.000346	CbGpPWpGaD
Sorafenib—CDK7—Disease—CD4—leprosy	2.43e-05	0.000345	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HLA-DRB1—leprosy	2.34e-05	0.000331	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HLA-DRB1—leprosy	2.33e-05	0.00033	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD40LG—leprosy	2.33e-05	0.00033	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—SDHD—leprosy	2.32e-05	0.000328	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—IL2—leprosy	2.32e-05	0.000328	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD8A—leprosy	2.3e-05	0.000326	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—CD4—leprosy	2.27e-05	0.000321	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL2—leprosy	2.23e-05	0.000315	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—RIPK2—leprosy	2.2e-05	0.000312	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—CD4—leprosy	2.18e-05	0.000309	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—TNF—leprosy	2.15e-05	0.000304	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HLA-DRB1—leprosy	2.1e-05	0.000298	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—RIPK2—leprosy	2.1e-05	0.000297	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—SDHD—leprosy	2.07e-05	0.000293	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—SDHD—leprosy	2.02e-05	0.000286	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL2—leprosy	2e-05	0.000284	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IFNG—leprosy	2e-05	0.000283	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—RIPK2—leprosy	1.96e-05	0.000278	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CD4—leprosy	1.93e-05	0.000273	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—SDHD—leprosy	1.9e-05	0.00027	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—SDHD—leprosy	1.89e-05	0.000267	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HLA-DRB1—leprosy	1.87e-05	0.000265	CbGpPWpGaD
Sorafenib—KIT—Immune System—IFNG—leprosy	1.8e-05	0.000255	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IFNG—leprosy	1.8e-05	0.000255	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL2—leprosy	1.77e-05	0.000251	CbGpPWpGaD
Sorafenib—BRAF—Disease—CD4—leprosy	1.76e-05	0.00025	CbGpPWpGaD
Sorafenib—KIT—Immune System—CD4—leprosy	1.74e-05	0.000246	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CD4—leprosy	1.74e-05	0.000246	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—leprosy	1.74e-05	0.000246	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—TNF—leprosy	1.72e-05	0.000244	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IFNG—leprosy	1.71e-05	0.000242	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IFNG—leprosy	1.7e-05	0.000241	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—RIPK2—leprosy	1.69e-05	0.00024	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CD4—leprosy	1.65e-05	0.000234	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD4—leprosy	1.65e-05	0.000233	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SDHD—leprosy	1.61e-05	0.000228	CbGpPWpGaD
Sorafenib—KIT—Disease—CD4—leprosy	1.6e-05	0.000227	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL2—leprosy	1.6e-05	0.000227	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL2—leprosy	1.6e-05	0.000227	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—IL2—leprosy	1.57e-05	0.000222	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IFNG—leprosy	1.53e-05	0.000217	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CD4—leprosy	1.52e-05	0.000216	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CD4—leprosy	1.52e-05	0.000215	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL2—leprosy	1.52e-05	0.000215	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL2—leprosy	1.51e-05	0.000214	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD4—leprosy	1.48e-05	0.00021	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL2—leprosy	1.42e-05	0.000202	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CD4—leprosy	1.37e-05	0.000194	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL2—leprosy	1.37e-05	0.000194	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IFNG—leprosy	1.37e-05	0.000194	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL2—leprosy	1.36e-05	0.000193	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL2—leprosy	1.33e-05	0.000189	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL2—leprosy	1.33e-05	0.000188	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD4—leprosy	1.32e-05	0.000187	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—IL2—leprosy	1.26e-05	0.000179	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SDHD—leprosy	1.24e-05	0.000176	CbGpPWpGaD
Sorafenib—RAF1—Disease—CD4—leprosy	1.22e-05	0.000173	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL2—leprosy	1.22e-05	0.000172	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL2—leprosy	1.15e-05	0.000163	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL2—leprosy	1.15e-05	0.000162	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL2—leprosy	1.14e-05	0.000161	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL2—leprosy	1.03e-05	0.000146	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL2—leprosy	1.03e-05	0.000146	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL2—leprosy	9.81e-06	0.000139	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL2—leprosy	9.79e-06	0.000139	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2—leprosy	8.82e-06	0.000125	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2—leprosy	8.41e-06	0.000119	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—leprosy	7.86e-06	0.000111	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—leprosy	6.78e-06	9.61e-05	CbGpPWpGaD
